Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04021706 · ClinicalTrials.gov registry record · Phase 1
Effect of a Ghrelin Receptor Agonist on Muscle and Bone
A Phase 1 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04021706 is a Phase 1 study that has completed, run by Tufts University. The registered enrollment target is 32 participants.
The verdict
NCT04021706, a Phase 1 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Adults with low muscle mass also usually have low bone mass, making them vulnerable to falls, fractures and other injuries. This project will determine the effectiveness of treatment with a ghrelin receptor agonist in improving short term indicators of muscle and bone health in adults with low bone and muscle mass. The results of this trial will inform the design of a larger, definitive randomized trial designed to establish efficacy.
Interventions
- DRUG Placebo
- DRUG Anamorelin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2023-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04021706
The ClinicalTrials.gov registry entry for NCT04021706 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04021706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04021706 about?
NCT04021706 is a clinical study titled "Effect of a Ghrelin Receptor Agonist on Muscle and Bone". Adults with low muscle mass also usually have low bone mass, making them vulnerable to falls, fractures and other injuries. This project will determine the effectiveness of treatment with a ghrelin receptor agonist in improving short term indicators of muscle and bone health in adults with low bone ...
What is the current status of trial NCT04021706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-12-05. Estimated completion is 2023-01-26.
What interventions are being tested in trial NCT04021706?
The interventions under investigation include: Placebo (DRUG), Anamorelin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04021706?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.